Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNDX POWR Grades
- Stability is the dimension where SNDX ranks best; there it ranks ahead of 48.15% of US stocks.
- The strongest trend for SNDX is in Momentum, which has been heading down over the past 47 weeks.
- SNDX's current lowest rank is in the Momentum metric (where it is better than 11.42% of US stocks).
SNDX Stock Summary
- Syndax Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.56% of US listed stocks.
- Of note is the ratio of Syndax Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 11.89% of US stocks have a lower such ratio.
- SNDX's price/sales ratio is 605.6; that's higher than the P/S ratio of 98.79% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Syndax Pharmaceuticals Inc are RNA, ZYME, SGMO, CRBP, and NTLA.
- SNDX's SEC filings can be seen here. And to visit Syndax Pharmaceuticals Inc's official web site, go to www.syndax.com.
SNDX Valuation Summary
- SNDX's price/earnings ratio is -8.9; this is 124.38% lower than that of the median Healthcare stock.
- Over the past 67 months, SNDX's price/sales ratio has gone up 228.3.
- Over the past 67 months, SNDX's price/sales ratio has gone up 228.3.
Below are key valuation metrics over time for SNDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SNDX | 2021-08-31 | 561.0 | 4.0 | -8.9 | -8.6 |
| SNDX | 2021-08-30 | 553.3 | 3.9 | -8.8 | -8.5 |
| SNDX | 2021-08-27 | 541.8 | 3.8 | -8.6 | -8.3 |
| SNDX | 2021-08-26 | 529.6 | 3.7 | -8.4 | -8.1 |
| SNDX | 2021-08-25 | 544.0 | 3.8 | -8.6 | -8.4 |
| SNDX | 2021-08-24 | 539.2 | 3.8 | -8.6 | -8.3 |
SNDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SNDX has a Quality Grade of D, ranking ahead of 19.5% of graded US stocks.
- SNDX's asset turnover comes in at 0.006 -- ranking 404th of 677 Pharmaceutical Products stocks.
- SYRS, GBT, and OPK are the stocks whose asset turnover ratios are most correlated with SNDX.
The table below shows SNDX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.006 | 1 | -0.517 |
| 2021-03-31 | 0.006 | 1 | -0.517 |
| 2020-12-31 | 0.008 | 1 | -0.570 |
| 2020-09-30 | 0.011 | 1 | -0.727 |
| 2020-06-30 | 0.014 | 1 | -0.906 |
| 2020-03-31 | 0.018 | 1 | -1.474 |
SNDX Price Target
For more insight on analysts targets of SNDX, see our SNDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.67 | Average Broker Recommendation | 1.36 (Strong Buy) |
SNDX Stock Price Chart Interactive Chart >
SNDX Price/Volume Stats
| Current price | $19.31 | 52-week high | $27.85 |
| Prev. close | $19.36 | 52-week low | $13.02 |
| Day low | $19.00 | Volume | 415,096 |
| Day high | $19.60 | Avg. volume | 654,723 |
| 50-day MA | $16.14 | Dividend yield | N/A |
| 200-day MA | $19.72 | Market Cap | 939.01M |
Syndax Pharmaceuticals, Inc. (SNDX) Company Bio
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.
Latest SNDX News From Around the Web
Below are the latest news stories about Syndax Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNDX as an investment opportunity.
Syndax Announces Participation at Three Upcoming Investor ConferencesSyndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences: |
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of... |
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue EstimatesSyndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2021. In addition, the Company provided a clinical and business update. |
10 Best Biotech Stocks to Buy According to Alan Frazier’s Frazier Healthcare PartnersIn this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier. If you want to skip our detailed analysis of Frazier’s history and hedge fund performance, go directly to the 5 Best Biotech Stocks to Buy According to Alan Frazier. Alan Frazier established Frazier Healthcare Partners in 1991. During his […] |
SNDX Price Returns
| 1-mo | 20.76% |
| 3-mo | 0.42% |
| 6-mo | -15.82% |
| 1-year | 10.47% |
| 3-year | 179.45% |
| 5-year | 28.65% |
| YTD | -13.17% |
| 2020 | 153.30% |
| 2019 | 97.30% |
| 2018 | -49.20% |
| 2017 | 22.18% |
| 2016 | N/A |
Continue Researching SNDX
Here are a few links from around the web to help you further your research on Syndax Pharmaceuticals Inc's stock as an investment opportunity:Syndax Pharmaceuticals Inc (SNDX) Stock Price | Nasdaq
Syndax Pharmaceuticals Inc (SNDX) Stock Quote, History and News - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...